Celltrion’s anti-inflammatory biosimilar Remsima SC, which is injected under the skin, gained approval from the European Medicines Agency as a treatment for inflammatory bowel disease. Remsima SC ...

18 th March 2016, Amsterdam, Netherlands. Real-world studies with nearly 600 inflammatory bowel disease (IBD) patients in eight countries show comparable efficacy and safety following a switch to ...

Celltrion said on the 19th that its autoimmune disease therapy Remsima SC (ingredient infliximab; U.S. brand name "Zymfentra") showed treatment efficacy in a post-hoc analysis of a phase 3 clinical ...

The studies, conducted across eight countries with nearly 600 inflammatory bowel disease (IBD) patients, further support claims by Celltrion that Remsima is highly similar its reference product. A ...

"Infliximab SC showed superiority over other formulations in improving maintenance therapy for patients with inflammatory bowel disease (IBD)." (Walter Reinisch, Professor at Medical University of ...

Celltrion announced on the 19th that it will participate in the 2026 European Crohn's and Colitis Organisation (ECCO) Congress, held in Stockholm, Sweden from February 18 to 21 (local time), where it ...

EXTON, Pa., Jan. 20, 2021 /PRNewswire/ -- Two 2020 European Medical Agency (EMA) approvals, Takeda's Entyvio SC and Celltrion Healthcare's infliximab biosimilar, Remsima SC, have captured notable ...

Celltrion Healthcare's Remsima SC has been prescribed "off-label" to IBD patients with success in the United Kingdom, according to industry officials, Tuesday. "Off-label" use means the medication is ...

Please provide your email address to receive an email when new articles are posted on . The intravenous and subcutaneous formulations of Remsima had comparable efficacy, safety and immunogenicity ...

Real-world studies with nearly 600 inflammatory bowel disease (IBD) patients in eight countries show comparable efficacy and safety following a switch to biosimilar infliximab from originator ...